Second-line chemotherapy in advanced biliary cancer: A systematic review

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2328-2338

  Lamarca, A ^a   Hubner, R A ^a   David Ryder, W ^a   Valle, Juan W ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Advanced biliary cancer; Chemotherapy; Second line; Systematic review

Indexed keywords

BORTEZOMIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; BILE DUCT CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DRUG RESPONSE; DRUG SAFETY; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BILIARY TRACT NEOPLASMS; DISEASE FREE SURVIVAL;

ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; TREATMENT OUTCOME;

EID: 84903528018     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu162     Document Type: Review

References (61)

1. Takada T, Amano H, Yasuda H et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95(8): 1685-1695.
2. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70(6): 1493-1497.
3. Eckel F, Brunner T, Jelic S. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(suppl 6): vi40-vi44.
4. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33(6): 1353-1357.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11-30.
6. Coleman MP. Cancer Survival Trends in England and Wales 1971-1995: deprivation and NHS region. UK: Stationery Office 1999.
7. Bertuccio P, Bosetti C, Levi F et al. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 2013; 24(6): 1667-1674.
8. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17(6): 1471-1474.
9. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7(6): 593-600.
10. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96(6): 896-902.
11. Tsavaris N, Kosmas C, Gouveris P et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22(2): 193-198.
12. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362(14): 1273-1281.
13. Okusaka T, Nakachi K, Fukutomi A et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103(4): 469-474.
14. Bridgewater J, Palmer D, Cunningham D et al. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 2013; 49(6): 1511.
15. http://www.crd.york.ac.uk/Prospero/(28 December 2013, date last accessed).
16. http://www.ncbi.nlm.nih.gov/(28 December 2013, date last accessed).
17. http://www.asco.org/(28 December 2013, date last accessed).
18. http://www.esmo.org/(28 December 2013, date last accessed).
19. http://annonc.oxfordjournals.org/content/by/year (28 December 2013, date last accessed).
20. Fervers B, Hardy J, Blanc-Vincent MP et al. SOR: project methodology. Br J Cancer 2001; 84(suppl 2): 8-16.
21. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
22. Matsuda T, Shikata S, Minato H et al. Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy. Gan To Kagaku Ryoho 2008; 35(10): 1779-1782.
23. Sang-Cheol L. Prognostic factor analysis of second-line chemotherapy in advanced biliary tract cancer. J Clin Oncol 2012; 30(suppl): abstr e14688.
24. Sasaki T, Isayama H, Nakai Y et al. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol 2013; 19(1): 72-77.
25. Mane J. Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC). J Clin Oncol 2011; 29(suppl 4): abstr 308.
26. Ueda S, Kawakami H, Okamoto W. Second-line chemotherapy with S-1 after cisplatin and gemcitabine failure in patients with advanced biliary tract cancer. Ann Oncol 2012; 23(suppl 4): iv65 (P0117).
27. Moretto R, Raimondo L, De Stefano A et al. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. Anticancer Drugs 2013; 24(9): 980-985.
28. Lee H-Y, Park J-J, Kwon K, Gun Seo B et al. Second-line treatment with mFOLFOX6 in Gemcitabine-pretreated pancreato-biliary cancer. Ann Oncol 2013; 4(suppl 4): iv31 (P0165).
29. Richard SF. A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. J Clin Oncol 2012; 30(suppl 4); abstr 220.
30. Pino MS, Milella M, Gelibter A et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009; 76(4): 254-261.
31. Lim JY, Jeung HC, Mun HS et al. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Anticancer Drugs 2008; 19(6): 631-635.
32. von Delius S, Lersch C, Schulte-Frohlinde E et al. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005; 5: 61.
33. Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11(1): 48-54.
34. Patt YZ, Hassan MM, Lozano RD et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 2001; 7(11): 3375-3380.
35. Lee S, Oh SY, Kim BG et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009; 32(4): 348-352.
36. Chiorean EG, Ramasubbaiah R, Yu M et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist 2012; 17(1): 13.
37. Sasaki T, Isayama H, Nakai Y et al. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011; 29(6): 1488-1493.
38. Oh SY, Jeong CY, Hong SC et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011; 29(5): 1066-1072.
39. Sasaki T, Isayama H, Yashima Y et al. S-1 Monotherapy in patients with advanced biliary tract cancer. Oncology 2009; 77(1): 71-74.
40. Suzuki E, Ikeda M, Okusaka T et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 2013; 71(5): 1141-1146.
41. Sasaki T, Isayama H, Nakai Y et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012; 30(2): 708-713.
42. Lim KH, Han SW, Oh DY et al. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology 2012; 83(2): 57-66.
43. Paule B, Herelle MO, Rage E et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007; 72(1-2): 105-110.
44. Sasaki T, Isayama H, Nakai Y et al. A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer. Anticancer Res 2013; 33(6): 2619-2622.
45. He S, Shen J, Sun X et al. A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother 2013 December 6 [epub ahead of print], doi: 1973947813Y0000000133.
46. Buzzoni R, Pusceddu S, Platania M et al. Efficacy and safety of RAD001 in advanced biliary tract cancer (BTC) patients ( pts) progressing after first-line chemotherapy: a phase II study. J Clin Oncol 2010; 28(15_suppl); abstr e14500.
47. Yi JH, Thongprasert S, Lee J et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012; 48(2): 196-201.
48. Roth A, Schleyer E, Schoppmeyer K et al. Imatinib mesylate for palliative secondline treatment of advanced biliary tract cancer: a bicentric phase II study. Onkologie 2011; 34(8-9): 469-470.
49. Costello MR, Meropol NJ, Denlinger CS et al. A phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135). J Clin Oncol 2009; 27(suppl); abstr e15605.
50. Kameda R, Ando T, Kobayshi S et al. Evaluation of chemotherapy with cisplatin plus gemcitabine after failure of gemcitabine alone for unresectable or recurrent biliary tract cancer. J Clin Oncol 2012; 29(15_suppl 4); abstr e14590.
51. Kiba T, Nishimura T, Matsumoto S et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology 2006; 70(5): 358-365.
52. Katayose Y, Ohtsuka H, Kitamura Y et al. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. Hepatogastroenterology 2012; 59(115): 691-695.
53. Brandi G, Di Girolamo S, de Rosa F et al. Second-line chemotherapy in patients with biliary tract cancer. J Clin Oncol 2011; 29(suppl); abstr e14590.
54. Kobayashi S, Ueno M, Ohkawa S et al. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol 2012; 42(9): 800-806.
55. Croitoru A, Gramaticu I, Dinu I et al. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma-a retrospective study. J Gastrointestin Liver Dis 2012; 21(3): 277-284.
56. Walter T, Horgan AM, McNamara M et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013; 49(2): 329-335.
57. Sasaki T, Isayama H, Nakai Y et al. A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer. Chemotherapy 2013; 59(2): 106-111.
58. Stemmler J, Heinemann V, Schalhorn A. Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. Onkologie 2002; 25(2): 182-184.
59. Lee MA, Woo IS, Kang JH et al. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol 2004; 34(9): 547-550.
60. Buzzoni R, Pusceddu S, Platania M et al. Efficacy and safety of RAD001 I advanced biliary tract cancer patients progressing after first-line chemotherapy: a phase II study. J Clin Oncol 2010; 28(15_suppl); abstr e14500.
61. Lee S-C, Kim K, Kim H et al. Prognostic factor analysis of second-line chemotherapy in advanced biliary tract cancer. J Clin Oncol 2012; 30(suppl); abstr e14688.